Globe Newswire (Tue, 23-Jun 4:05 PM ET)
Agomab Announces Results of Annual General Meeting
Globe Newswire (Wed, 27-May 5:00 AM ET)
Agomab to Participate in Upcoming Conferences
Globe Newswire (Thu, 14-May 7:30 AM ET)
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
Globe Newswire (Thu, 23-Apr 6:14 PM ET)
Agomab Raises $200 Million in Nasdaq Debut: What the IPO Means for Biopharma Investors
Market Chameleon (Tue, 10-Feb 3:22 AM ET)
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Agomab Therapeutics Nv - Adrs Representing One Common Share. trades on the NASDAQ stock market under the symbol AGMB.
As of July 21, 2026, AGMB stock price declined to $11.64 with 107,632 million shares trading.
AGMB has a beta of 1.19, meaning it tends to be more sensitive to market movements. AGMB has a correlation of 0.06 to the broad based SPY ETF.
AGMB has a market cap of $572.92 million. This is considered a Small Cap stock.
AGMB support price is $11.06 and resistance is $12.90 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGMB shares will trade within this expected range on the day.
